Skip To Main Content
Lilly
Menu closed
Lilly
  • Account Login / Register
  • Medical Home
    • Medical Information
  • Medical Education
  • Science
Ask Lilly

We're here to help.

Chat
Chat with us Chat with us
Question Contact Us
Expand contact lilly
Lilly

You are now leaving the Lilly Medical website

The link you clicked on will take you to a site maintained by a third party, which is solely responsible for its content. Lilly USA, LLC does not control, influence, or endorse this site, and the opinions, claims, or comments expressed on this site should not be attributed to Lilly USA, LLC. Lilly USA, LLC is not responsible for the privacy policy of any third-party websites. We encourage you to read the privacy policy of every website you visit.
Click "Continue" to proceed or "Return" to return to Lilly Medical

  1. Medical Information Right
  2. Diabetes Right
  3. Mounjaro (tirzepatide) injection Right
  4. How should Mounjaro® (tirzepatide) doses be increased?
Search Mounjaro (tirzepatide) injection (type in keywords)
Search Medical Information

If you wish to report an adverse event or product complaint, please call 1-800-LILLYRX (1-800-545-5979)

Loading icon

Mounjaro ® (tirzepatide) injection

2.5 mg/5 mg/7.5 mg/10 mg/12.5 mg/15 mg

Full Prescribing Information

This information is provided in response to your request. Resources may contain information about doses, uses, formulations and populations different from product labeling. See Prescribing Information above, if applicable.

How should Mounjaro® (tirzepatide) doses be increased?

Tirzepatide should be initiated at 2.5 mg subcutaneously once weekly and increased in 2.5 mg increments every 4 weeks until target dose is achieved, up to a maximum dose of 15 mg.

US_cFAQ_TZP003_DOSE_ESCALATION_T2D
US_cFAQ_TZP003_DOSE_ESCALATION_T2Den-US

See important safety information, including boxed warning, in the attached prescribing information.

What is the Tirzepatide Recommended Dosing? 

The recommended starting dose of tirzepatide is 2.5 mg injected subcutaneously once weekly. Follow the dosage escalation below to reduce the risk of gastrointestinal adverse reactions.​ The 2.5 mg dosage is for treatment initiation and is not intended for glycemic control.1

After 4 weeks, increase the dosage to 5 mg once weekly.1

If additional glycemic control is needed, increase the dosage in 2.5 mg increments after at least 4 weeks on the current dose.1

The maximum dose of tirzepatide is 15 mg once weekly.1

Administer tirzepatide

  • once weekly
  • any time of day, and
  • with or without meals.1

Tirzepatide should be injected subcutaneously in the abdomen, thigh, or upper arm.1

Dose Escalation in Tirzepatide Clinical Studies

In the phase 3 studies of tirzepatide in type 2 diabetes (SURPASS-1 to -5), participants were assigned to 1 of 3 tirzepatide treatment arms (5, 10, or 15 mg) for assessment of efficacy and safety (Dose Escalation Schedule for Tirzepatide in Phase 3 Clinical Studies).2-6

Dose Escalation Schedule for Tirzepatide in Phase 3 Clinical Studies2-6

Figure 1 description: Patients receiving tirzepatide in the tirzepatide phase 3 clinical studies in patients with type 2 diabetes, received a starting dose of tirzepatide 2.5 mg once weekly for 4 weeks and were escalated in 2.5 mg increments every 4 weeks until the assigned dose was achieved (5, 10, or 15 mg). 

The starting dose of tirzepatide was 2.5 mg once weekly for 4 weeks and escalated in 2.5 mg increments every 4 weeks until the assigned dose was achieved.2-6

Dose escalation in 2.5 mg increments at 4 week intervals was chosen based on the ability to improve the tolerability profile.2

The 3 tirzepatide doses (5, 10, and 15 mg) studied for efficacy in the SURPASS phase 3 clinical study program were identified based on the safety, efficacy, and exposure response modeling of data in participants with type 2 diabetes in phase 1 and 2 studies.2

Enclosed Prescribing Information

MOUNJARO® (tirzepatide) injection, for subcutaneous use, Lilly

References

The published references below are available by contacting 1-800-LillyRx (1-800-545-5979).

1Mounjaro [package insert]. Indianapolis, IN: Eli Lilly and Company; 2024.

2Rosenstock J, Wysham C, Frías JP, et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial. Lancet. 2021;398(10295):143-155. https://doi.org/10.1016/S0140-6736%2821%2901324-6

3Frías JP, Davies MJ, Rosenstock J, et al; SURPASS-2 Investigators. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. N Engl J Med. 2021;385(6):503-515. https://doi.org/10.1056/NEJMoa2107519

4Ludvik B, Giorgino F, Jódar E, et al. Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial. Lancet. 2021;398(10300):583-598. https://doi.org/10.1016/S0140-6736(21)01443-4

5Del Prato S, Kahn SE, Pavo I, et al; SURPASS-4 Investigators. Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial. Lancet. 2021;398(10313):1811-1824. https://doi.org/10.1016/S0140-6736(21)02188-7

6Dahl D, Onishi Y, Norwood P, et al. Effect of subcutaneous tirzepatide vs placebo added to titrated insulin glargine on glycemic control in patients with type 2 diabetes: the SURPASS-5 randomized clinical trial. JAMA. 2022;327(6):534-545. https://doi.org/10.1001/jama.2022.0078

Date of Last Review: January 22, 2025

Are you satisfied with this content?

Can't find what you're looking for? Contact us for answers to your medical questions.

  • Copyright
  • Terms of Use
  • Privacy Statement
  • Consumer Health Privacy Notice
  • Accessibility Statement
  • Sitemap

    This site is intended for US Healthcare Professionals only.

    4.0.43 4/2025 | GLOOTH00001 04/2015 | © Lilly USA, LLC 2025. All rights reserved.

    Product names listed above are trademarks or registered trademarks owned by or licensed to Eli Lilly and Company, its subsidiaries, or affiliates

    California Consumer Privacy Act (CCPA) Opt-Out Icon Your Privacy Choices
    Cookie Settings
    facebook twitter linkedin
    visit www.phactmi.org
    Lilly